Humanized Anti-IL-5 Antibody Therapy
- PMID: 27104969
- DOI: 10.1016/j.cell.2016.04.020
Humanized Anti-IL-5 Antibody Therapy
Abstract
Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years.
Copyright © 2016 Elsevier Inc. All rights reserved.
LinkOut - more resources
Full Text Sources
Other Literature Sources